Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Atopic Dermatitis disease market through 2033.
GlobalData estimated that the atopic dermatitis market was $10.8 billion across the 68MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $26.2 billion, increasing at a compound annual growth rate (CAGR) of 9.3%. This strong growth will be fuelled by driven by the launch of seven late-stage pipeline agents in the 7MM, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast period.
Scope
Overview of AD – including epidemiology, disease etiology and management.
Annualized atopic dermatitis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.
Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers.
Key Highlights
The AD market will exhibit significant growth between 2020 and 2030, driven by the entry of several pipeline agents including IL and JAK inhibitors as well as topical therapies for the treatment of mild to moderate AD. These new entrants will transform the AD market by providing more treatment options for patients across severities and age groups.
Dupixent (dupilumab) will continue to be the market leader with estimated peak sales of $6.2 billion in 2030. It is already known as the gold standard for the treatment of moderate to severe AD across the 7MM
KOLs expressed enthusiasm for the late-stage agents etrasimod, a sphingosine-1-phosphate receptor-1 (S1PR) modulator, and rocatinlimab (KHK4083), an anti-OX40 mAb, due to their new mechanisms of action and the innovation they would bring to the market; if approved they would both be the first in their respective classes.
The most important unmet needs in AD are the lack of therapeutic options for chronic hand eczema (CHE), better long-term disease control and management, as well as more tolerable topical treatment options
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the atopic dermatitis (AD) therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the seven-market AD therapeutics market from 2023-2033.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Aclaris Therapeutics
Almirall
Amgen
AOBiome Therapeutics
Apollo Therapeutics
Arcutis Biotherapeutics
Dermavant Sciences
Eli Lilly
Evommune
Galderma
ImageneBio
Incyte
Kymera Therapeutics
Kyowa Kirin
Leo Pharma
Maruho
Nektar Therapeutics
Organon
Otsuka
Pfizer
Regeneron
Sanofi
UCB
Union Therapeutics
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Atopic Dermatitis (Atopic Eczema) reports